var data={"title":"Penicillin G (intravenous and short-acting intramuscular): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Penicillin G (intravenous and short-acting intramuscular): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6743?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-patient-drug-information\" class=\"drug drug_patient\">see &quot;Penicillin G (intravenous and short-acting intramuscular): Patient drug information&quot;</a> and <a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Penicillin G (intravenous and short-acting intramuscular): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207660\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Pfizerpen;</li>\n      <li>Pfizerpen-G</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207661\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Crystapen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207680\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Penicillin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207664\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range: </b>IM, IV: 12 to 24 million units/day in divided doses every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Actinomyces </i></b> <b>species:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cervicofacial disease: 1 to 6 million units/day in divided doses every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Thoracic and abdominal disease: 10 to 20 million units/day in divided doses every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anthrax:</b> IV: Minimum 8 million units/day in divided doses every 6 hours; higher doses may be required depending on the susceptibility of the organism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Clostridium </i></b> <b>species:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer's labeling:</i> Botulism, gas gangrene, tetanus: 20 million units/day in divided doses every 4 to 6 hours; adjunctive therapies for botulism and tetanus (eg, botulinum antitoxin, tetanus immune globulin) are also recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternate recommendations:</i> Skin and soft tissue necrotizing infections (off-label use): 2 to 4 million units every 4 to 6 hours; use in combination with clindamycin and continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Cutibacterium acnes</i> infection of deep-brain stimulation hardware (off-label use):</b> IV: 24 million units/day in divided doses every 4 hours (Tunkel 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diphtheria (adjunctive therapy to antitoxin and for prevention of carrier state):</b> IV: 2 to 3 million units/day in divided doses every 4 to 6 hours for 10 to 12 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, treatment:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Enterococcus, native or prosthetic valve (penicillin-susceptible/gentamicin-susceptible strains) (off-label dose):</i> 18 to 30 million units/day as continuous infusion or in divided doses every 4 hours with concomitant gentamicin. Duration of therapy: 4 weeks (native valve <b>and</b> symptoms present &lt;3 months); 6 weeks (native valve <b>and</b> symptoms present &ge;3 months <b>or</b> prosthetic valve) (AHA [Baddour 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Enterococcus, native or prosthetic valve (penicillin-susceptible/streptomycin-susceptible/gentamicin-resistant strains) (off-label dose):</i> 18 to 30 million units/day as continuous infusion or in divided doses every 4 hours with concomitant streptomycin. Duration of therapy: 4 weeks (native valve <b>and</b> symptoms present &lt;3 months); &ge;6 weeks (native valve <b>and</b> symptoms present &ge;3 months <b>or</b> prosthetic valve) (AHA [Baddour 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Erysipelothrix rhusiopathiae:</i> 12 to 20 million units/day in divided doses every 4 to 6 hours for 4 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Listeria monocytogenes: </i>15 to 20 million units/day in divided doses every 4 to 6 hours for 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Viridans group streptococcus (VGS) and S. bovis (off-label dose) (AHA [Baddour 2015]):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Native valve: Highly penicillin-susceptible (MIC &le;0.12 mcg/mL): 12 to 18 million units/day as continuous infusion or in divided doses every 4 or 6 hours for 4 weeks <b>or</b> 12 to 18 million units/day as continuous infusion or in divided doses every 6 hours for 2 weeks with concomitant gentamicin</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Native valve: Relatively penicillin-resistant (MIC &gt;0.12 to &lt;0.5 mcg/mL): 24 million units/day as continuous infusion or in divided doses every 4 or 6 hours for 4 weeks with concomitant gentamicin for the first 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Prosthetic valve: Highly penicillin-susceptible (MIC &le;0.12 mcg/mL): 24 million units/day as continuous infusion or in divided doses every 4 or 6 hours for 6 weeks (with or without concomitant gentamicin for the first 2 weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Prosthetic valve: Relatively or fully penicillin-resistant (MIC &gt;0.12 mcg/mL): 24 million units/day as continuous infusion or in divided doses every 4 or 6 hours with concomitant gentamicin for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Fusospirochetosis (including Vincent disease):</b> IV: 5 to 10 million units/day in divided doses every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Leptospirosis (off-label use):</b> IV: 1.5 million units every 6 hours for 7 days (Panaphut 2003; Suputtamongkol 2004; Watt 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lyme neuroborreliosis (off-label use):</b> IV: 3 to 4 million units every 4 hours (Halperin 2007; Halperin 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningitis, bacterial: As a component of pathogen-specific therapy (eg,</b>\n      <i>\n        <b> Listeria, Neisseria</b></i>\n      <b>\n        <i> meningitidis </i>[with MIC <b>&le;0.1 mcg/mL</b><b>]</b></b>\n      <b>,</b>\n      <i>\n        <b> Cutibacterium </b></i>\n      <i>\n        <b>acnes, </b></i>\n      <b>or</b>\n      <i>\n        <b> Streptococcus pneumoniae </b></i>\n      <b>[with MIC &le;0.06 mcg/mL]</b>\n      <b>):</b> IV: 4 million units every 4 hours (Hof 1997; IDSA [Tunkel 2004; Tunkel 2017]; Medoff 1971). In patients with meningitis due to <i>Listeria</i>, combination with an aminoglycoside is recommended (Drevets 1994; Hof 1997).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neurosyphilis:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer's labeling: </i> 2 to 4 million units every 4 hours for 10 to 14 days; after completion, additional therapy with benzathine penicillin G may be warranted</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternate recommendations includes ocular syphilis (off-label dose):</i> 18 to 24 million units/day in divided doses every 4 hours (or by continuous infusion) for 10 to 14 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Osteomyelitis, native vertebral (off-label use) (IDSA [Berbari 2015]): </b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Enterococcus spp (penicillin-susceptible) </i>or <i>streptococci (beta-hemolytic):</i> 20 to 24 million units/day as a continuous infusion or in divided doses every 4 hours for 6 weeks. <b>Note: </b>In patients with infective endocarditis due to penicillin-susceptible <i>Enterococcus</i> spp, the addition of an aminoglycoside for 4 to 6 weeks is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Cutibacterium acnes: </i>20 million units/day as a continuous infusion or in divided doses every 4 hours for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Pasteurella </i></b> <b>infections (bacteremia, meningitis):</b> IV: 4 to 6 million units/day in divided doses every 4 to 6 hours for 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prosthetic joint infection (off-label use): </b>IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Enterococcus spp (penicillin-susceptible), streptococci (beta-hemolytic):</i> 20 to 24 million units/day as a continuous infusion every 24 hours or in divided doses every 4 hours for 4 to 6 weeks (Osmon 2013); <b>Note: </b> For penicillin-susceptible <i>Enterococcus</i> spp, consider addition of aminoglycoside.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cutibacterium acnes:</i> 20 million units/day as a continuous infusion every 24 hours or in divided doses every 4 hours for 4 to 6 weeks (Osmon 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rat bite fever (including Haverhill fever): </b>IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Uncomplicated infection:</i> 200,000 units every 4 hours for 5 to 7 days; if patient clinically improves after initial IV course, may switch to oral therapy (eg, penicillin V, amoxicillin) to complete a 14 day course (CDC 2005; King 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Serious invasive infection:</i> 12 to 18 million units/day as a continuous infusion every 24 hours or in divided doses every 4 to 6 hours for 4 weeks; may increase dose to 24 million units/day in patients with an isolate that is not highly penicillin susceptible (King 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Streptococcus infections: </b>IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Group B streptococcus, maternal dose (neonatal prophylaxis) (off-label use):</i> 5 million units x 1 dose, then 2.5 to 3 million units every 4 hours until delivery (CDC 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Skin infections, including skin and soft tissue necrotizing infections (off-label use):</i> 2 to 4 million units every 4 to 6 hours; use in combination with clindamycin for necrotizing infections and continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Group A streptococcus invasive infection, severe:</i> 3 to 4 million units every 4 hours with clindamycin for 10 to 14 days (Walker 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Streptococcal pneumonia:</b> IV: 12 to 24 million unit/day in divided doses every 4 to 6 hours. <b>Note: </b> Only recommended for <i>S. pneumoniae</i> when MIC is &lt;2 mcg/mL (Mandell 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Whipple disease (off-label use):</b> IV: 2 to 4 million units every 4 hours for 2 to 4 weeks, followed by oral trimethoprim/sulfamethoxazole monotherapy <b>or</b> oral doxycycline and hydroxychloroquine for 1 year (Bures 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207675\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Penicillin G (intravenous and short-acting intramuscular): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infections </b>(<i>Red Book</i> [AAP 2015])<b>:</b> Infants, Children, and Adolescents: IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate infection: 100,000 to 150,000 units/kg/day in divided doses every 6 hours; maximum daily dose: 8 million units/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe infection: 200,000 to 300,000 units/kg/day in divided doses every 4 to 6 hours; maximum daily dose: 24 million units/day; <b>Note:</b> Use highest dose in range for CNS infections.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anthrax, systemic (inhalational):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Non-CNS infection:</i> Infants, Children, and Adolescents: IV: 400,000 units/kg/day in divided doses every 4 hours; maximum dose: 4 million units/dose; use in combination with clindamycin, linezolid, doxycycline or rifampin for &ge;14 days until clinical stability is achieved (ie, appear well with no signs or symptoms of active infection and can tolerate oral therapy); treatment must be followed by prophylaxis for a total antibiotic course of 60 days (AAP [Bradley 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Meningitis:</i> Infants, Children, and Adolescents: IV: 400,000 units/kg/day in divided doses every 4 hours; maximum dose: 4 million units/dose; use in combination with a fluoroquinolone plus linezolid, clindamycin, rifampin, or chloramphenicol for &ge;2 to 3 weeks until clinical stability is achieved (ie, appear well with no signs or symptoms of active infection and can tolerate oral therapy); treatment must be followed by prophylaxis for a total antibiotic course of 60 days (AAP [Bradley 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Clostridial myonecrosis (gas gangrene):</b> Infants, Children, and Adolescents: IV: 250,000 to 400,000 units/kg/day in divided doses every 4 to 6 hours with or without clindamycin (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diphtheria:</b> Infants, Children, and Adolescents: IM, IV: 150,000 to 250,000 units/kg/day in divided doses every 6 hours for 7 to 10 days. AAP suggests a duration of 14 days (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis, bacterial, treatment</b>: Children and Adolescents: IV: 200,000 to 300,000 units/kg/day in divided doses every 4 hours; maximum daily dose: 24 million units/day; treat for at least 4 weeks; longer durations may be necessary; may use in combination with gentamicin for some resistant organisms (AHA [Baltimore 2015]). <b>Note:</b> For endocarditis from rat-bite fever/haverhill fever, the manufacturer recommends a lower dose of 150,000 to 250,000 units/kg/day in divided doses every 4 hours; maximum daily dose: 20 million units/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lyme disease (off-label use):</b> Infants, Children, and Adolescents: IV: 200,000 to 400,000 units/kg/day in divided doses every 4 hours; maximum daily dose: 24 million units/day (AAN [Halperin 2007]; IDSA [Wormser 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningitis:</b> IV: <b>Note:</b> Dosing varies based on organism being treated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Group B streptococcus:</i> Infants: 450,000 to 500,000 units/kg/day divided every 6 hours (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>S. pneumoniae:</i> Infants, Children, and Adolescents: 250,000 to 400,000 units/kg/day divided every 4 to 6 hours (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Other susceptible organisms:</i> Infants, Children, and Adolescents: 300,000 units/kg/day divided every 4 to 6 hours; maximum daily dose: 24 million units/day (Tunkel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningococcal disease:</b> IV: Infants, Children, and Adolescents: 300,000 units/kg/day in divided doses every 4 to 6 hours; maximum daily dose: 12 million units/day (<i>Red Book </i>[AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, community-acquired (CAP):</b> Infants &gt;3 months and Children:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Empiric treatment or <i>S. pneumoniae</i> (moderate to severe; MICs to penicillin &le;2 mcg/mL): IV: 200,000 to 250,000 units/kg/day divided every 4 to 6 hours (IDSA/PIDS [Bradley 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing (AAP recommendation): IV: 250,000 to 400,000 units/kg/day divided every 4 to 6 hours (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Group A <i>Streptococcus</i> (moderate to severe): IV: 100,000 to 250,000 units/kg/day divided every 4 to 6 hours (IDSA/PIDS [Bradley 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and soft tissue necrotizing infections due to </b>\n      <i>\n        <b>Clostridium</b></i>\n      <b> species (off-label use):</b> IV: Infants, Children, and Adolescents: 60,000 to 100,000 units/kg/<b>dose</b> every 6 hours; use in combination with clindamycin and continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Streptococcal skin infections, including skin and soft tissue necrotizing infections (off-label use):</b> IV: Infants, Children, and Adolescents: 60,000 to 100,000 units/kg/<b>dose</b> every 6 hours; maximum dose: 4 million units/dose; use in combination with clindamycin for necrotizing infections and continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Syphilis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Congenital: Infants and Children: IV: 50,000 units/kg/<b>dose</b> every 4 to 6 hours for 10 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neurosyphilis (including ocular syphilis):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children: IV: 50,000 units/kg/<b>dose</b> every 4 to 6 hours for 10 to 14 days; maximum daily dose: 24 million units/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: IV: 3 to 4 million units every 4 hours or as a continuous infusion for 10 to 14 days; maximum daily dose: 24 million units/day (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tetanus:</b> Infants, Children, and Adolescents: IV: 100,000 units/kg/day in divided doses every 4 to 6 hours for 7 to 10 days; maximum daily dose: 12 million units/day (<i>Red Book</i> [AAP 2015])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207665\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207666\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Manufacturer's labeling:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Uremic patients with CrCl &gt;10 mL/minute/1.73 m<sup>2</sup>: Administer a usual recommended dose followed by 50% of the usual recommended dose every 4 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer a normal dose followed by 50% of the normal dose every 8 to 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Alternate recommendation:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GFR &gt;50 mL/minute: No dosage adjustment necessary (Aronoff 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GFR 10-50 mL/minute: Administer 75% of the normal dose (Aronoff 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GFR &lt;10 mL/minute: Administer 20% to 50% of the normal dose (Aronoff 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease on intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days) (Heintz 2009): Administer a normal dose followed by either 25% to 50% of normal dose every 4 to 6 hours <b>or</b> 50% to 100% of normal dose every 8 to 12 hours. For <i>mild-to-moderate</i> infections, administer 0.5 to 1 million units every 4 to 6 hours <b>or</b> 1 to 2 million units every 8 to 12 hours. For <i>neurosyphilis, endocarditis, or serious infections</i>, administer up to 2 million units every 4 to 6 hours;  administer after dialysis on dialysis days <b>or</b> supplement with 500,000 units after dialysis. <b>Note:</b> Dosing dependent on the assumption of 3 times weekly, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CVVH: Loading dose of 4 million units, followed by 2 million units every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CVVHD: Loading dose of 4 million units, followed by 2 to 3 million units every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CVVHDF: Loading dose of 4 million units, followed by 2 to 4 million units every 4 to 6 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22154815\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. However, the manufacturer's labeling recommends further adjustment of doses adjusted for renal impairment in patients with both renal and hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207638\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as potassium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20,000 units/mL (50 mL); 40,000 units/mL (50 mL); 60,000 units/mL (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as potassium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pfizerpen-G: 5,000,000 units (1 ea); 20,000,000 units (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pfizerpen-G: 5,000,000 units (1 ea); 20,000,000 units (1 ea) [pyrogen free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5,000,000 units (1 ea); 20,000,000 units (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as potassium [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pfizerpen: 5,000,000 units (1 ea); 20,000,000 units (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20,000,000 units (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5,000,000 units (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207622\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207642\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Administer IM by deep injection in the upper outer quadrant of the buttock. Administer injection around-the-clock to promote less variation in peak and trough levels.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Usually administered by intermittent infusion. In some centers, large doses may be administered by continuous IV infusion. <b>Note:</b> The 20 million unit dosage form may be administered by IV infusion only.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intermittent IV:</i> Infuse over 15 to 30 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207641\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anthrax:</b> Treatment of anthrax caused by <i>Bacillus anthracis</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Actinomycosis</b>: Treatment of actinomycosis (cervicofacial disease and thoracic and abdominal disease) caused by <i>Actinomyces israelii</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Clostridial infections: </b>Treatment of botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) caused by <i>Clostridium</i> spp.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diphtheria: </b>Treatment of diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) caused by <i>Corynebacterium diphtheriae</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Erysipelothrix endocarditis: </b>Treatment of erysipelothrix endocarditis caused by <i>Erysipelothrix rhusiopathiae</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fusospirochetosis: </b>Treatment of fusospirochetosis, including severe infections of the oropharynx [Vincent], lower respiratory tract and genital area, caused by <i>Fusobacterium</i> spp. and spirochetes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Listeria infections: </b>Treatment of listeria infections, including meningitis and endocarditis, caused by <i>Listeria monocytogenes</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningococcal infection: </b>Treatment of meningococcal meningitis and/or septicemia caused by <i>Neisseria meningitidis</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pasteurella infections: </b>Treatment of pasteurella infections, including bacteremia and meningitis, caused by <i>Pasteurella multocida</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rat bite fever:</b> Treatment of rat bite fever (including Haverhill fever) caused by <i>Spirillum minus</i> or <i>S. moniliformis</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Serious gram-positive infections:</b> Treatment of septicemia, empyema, pneumonia, pericarditis, endocarditis, and meningitis caused by <i>Streptococcus pyogenes</i> (group A beta-hemolytic streptococcus), other beta-hemolytic streptococci including groups C, H, G, L and M, <i>Streptococcus pneumoniae</i> and <i>Staphylococcus</i> species (nonpenicillinase-producing strains)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Syphilis:</b> Treatment of syphilis (congenital and neurosyphilis) caused by <i>Treponema pallidum</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25860681\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Community-acquired pneumonia (children); Cutibacterium acnes infection of deep-brain stimulation hardware; Group B streptococcus, maternal dose (neonatal prophylaxis); Leptospirosis; Lyme neuroborreliosis; Osteomyelitis, native vertebral; Prosthetic joint infection; Skin and soft tissue infections; Whipple Disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207689\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Penicillin may be confused with penicillamine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207629\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Localized phlebitis, local thrombophlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Coma (high doses), hyperreflexia (high doses), myoclonus (high doses), seizure (high doses)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Contact dermatitis, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Electrolyte disturbance (high doses)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Pseudomembranous colitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Neutropenia, positive direct Coombs test (rare, high doses)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction (immediate and delayed), serum sickness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Immunologic: Jarisch-Herxheimer reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Acute interstitial nephritis (high doses), renal tubular disease (high doses)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207645\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to any penicillin or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for beta-lactams (eg, penicillins and cephalosporins) is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207626\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity (including cephalosporins) or history of sensitivity to multiple allergens. Use with caution in asthmatic patients. If a serious reaction occurs, discontinue treatment and institute supportive measures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurovascular damage: Avoid intra-arterial administration or injection into or near major peripheral nerves or blood vessels since such injections may cause severe and/or permanent neurovascular damage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended. In the presence of concomitant hepatic impairment, further dosage adjustment may be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates: Neonates may have decreased renal clearance of penicillin and require frequent dosage adjustments depending on age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte imbalance: Product contains sodium and potassium; high doses of IV therapy may alter serum levels. If high doses (eg, &gt;10 million units) are used, administer at a slower rate (eg, &gt;30 minutes for intermittent IV infusion).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299838\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OAT3</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207631\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9749&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Penicillins. Management: Avoid the routine use of penicillins and probenecid, but this combination may be used advantageously in select cases with careful monitoring. Monitor for toxic effects of penicillins if probenecid is initiated or the dose is increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OAT3 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5720623\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Penicillin G crosses the placenta. Maternal use of penicillins has generally not resulted in an increased risk of adverse fetal effects. Penicillin G is the drug of choice for treatment of syphilis during pregnancy and penicillin G (parenteral/aqueous) is the drug of choice for the prevention of early-onset Group B Streptococcal (GBS) disease in newborns (consult current guidelines) (CDC (RR-10) 2010; CDC [Workowski 2015]). When IV therapy is required for anthrax infection in pregnant and postpartum women, penicillin G may be used as an alternative agent (Meaney-Delman 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5707425\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Penicillin G is present in breast milk. The manufacturer recommends that caution be exercised when administering penicillin G to breastfeeding women. Peak milk concentrations occur at approximately 1 hour after an IM dose and are higher if multiple doses are given (Greene 1946; Matsuda 1984). Nondose-related effects could include modification of bowel flora and allergic sensitization.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F678881\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain potassium and/or sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207636\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic electrolyte, hepatic, renal, cardiac and hematologic function tests during prolonged/high-dose therapy; observe for signs and symptoms of anaphylaxis during first dose. In older adults, especially those with decreased renal function, monitor for seizure activity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207625\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferes with bacterial cell wall synthesis during active multiplication, causing cell wall death and resultant bactericidal activity against susceptible bacteria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207644\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Poor penetration across blood-brain barrier, despite inflamed meninges</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Relative diffusion from blood into CSF: Poor unless meninges inflamed (exceeds usual MICs)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CSF:blood level ratio: Inflamed meninges: 2% to 6%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: &lt;6 days of age: 3.1 hours; &ge;14 days of age: 1.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Normal renal function: 31 to 50 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ESRD): 6 to 20 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: IV: Immediately after infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (58% to 85% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323647\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Penicillin G Potassium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000000 unit (1): $42.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20000000 unit (1): $138.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Penicillin G Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000000 unit (1): $57.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Pfizerpen Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000000 unit (1): $15.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20000000 unit (1): $60.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Pfizerpen-G Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000000 unit (1): $15.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20000000 unit (1): $60.76</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207648\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Benpen (AU, NZ);</li>\n      <li>Bentapen (PH);</li>\n      <li>Broncobiot (PE);</li>\n      <li>Lascacilin (PY);</li>\n      <li>Pencarv (PH);</li>\n      <li>Pengesod (MX);</li>\n      <li>Penicilina Northia (AR);</li>\n      <li>Penicillin G (BG);</li>\n      <li>Penicillin G- Natrium (AT);</li>\n      <li>Pisacilina (CO);</li>\n      <li>Sodipen (MX);</li>\n      <li>Unicil 1 Mega (CO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds; <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Infectious Diseases, &ldquo;Treatment of Bacterial Meningitis,&rdquo; <i>Pediatrics</i>, 1988, 81(6):904-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/3368290/pubmed\" target=\"_blank\" id=\"3368290\">3368290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association [published correction appears in <i>Circulation</i>. 2015;132(17):e215]. <i>Circulation</i>. 2015;132(15):1435-1486.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/26373316/pubmed\" target=\"_blank\" id=\"26373316\">26373316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation.</i> 2015;132(15):1487-1515. doi: 10.1161/CIR.0000000000000298.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):26-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/26229122/pubmed\" target=\"_blank\" id=\"26229122\">26229122</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bonnetblanc JM, B&eacute;dane C. Erysipelas: recognition and management. <i>Am J Clin Dermatol</i>. 2003;4(3):157-163.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/12627991/pubmed\" target=\"_blank\" id=\"12627991\">12627991</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al. &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Peacock G, Krug SE, et al; AAP Committee on Infectious Diseases and Disaster Preparedness Advisory Council. Pediatric anthrax clinical management. <i>Pediatrics.</i> 2014;133(5):e1411-1436. doi: 10.1542/peds.2014-0563.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/24777226/pubmed\" target=\"_blank\" id=\"24777226\">24777226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23843784\"></a>Bure&scaron; J, Kop&aacute;&#269;ov&aacute; M, Douda T, et al. Whipple's disease: our own experience and review of the literature. <i>Gastroenterol Res Pract</i>. 2013;2013:478349.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/23843784/pubmed\" target=\"_blank\" id=\"23843784\">23843784</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Fatal rat-bite fever--Florida and Washington, 2003. <i>MMWR Morb Mortal Wkly Rep.</i> 2005;53(51):1198-1202.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/15635289/pubmed\" target=\"_blank\" id=\"15635289\">15635289</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21088663\"></a>Centers for Disease Control and Prevention (CDC). Prevention of perinatal Group B Streptococcal Disease, Revised Guidelines from CDC, 2010. <i>MMWR Recomm Rep.</i> 2010;59(RR-10):1-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/21088663/pubmed\" target=\"_blank\" id=\"21088663\">21088663</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 12, 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo; <i>N Engl J Med</i>, 1988, 318(7):419-26 and 318(8):490-500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/3277054/pubmed\" target=\"_blank\" id=\"3277054\">3277054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Drevets DA, Canono BP, Leenen PJ, et al. Gentamicin kills intracellular Listeria monocytogenes. <i>Infect Immun.</i> 1994;62(6):2222-2228.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/8188344/pubmed\" target=\"_blank\" id=\"8188344\">8188344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9193452\"></a>Durand DV, Lecomte C, Cath&eacute;bras P, Rousset H, Godeau P. Whipple disease. Clinical review of 52 cases. The SNFMI Research Group on whipple disease. Soci&eacute;t&eacute; Nationale Fran&ccedil;aise de M&eacute;decine Interne. <i>Medicine (Baltimore)</i>. 1997;76(3):170-184.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/9193452/pubmed\" target=\"_blank\" id=\"9193452\">9193452</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilbert DN, Moellering RC, Eliopoulos GM, et al, eds, <i>The Sanford Guide To Antimicrobial Therapy</i>, 2006, 36th ed, Hyde Park, VT: Antimicrobial Therapy, Inc, 2006, 6-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greene HJ, Burkhart B, Hobby GL. Excretion of penicillin in human milk following parturition. <i>Am J Obstet Gyn.</i> 1946;51:732-733.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/21025164/pubmed\" target=\"_blank\" id=\"21025164\">21025164</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Halperin JJ. Nervous system lyme disease: diagnosis and treatment. <i>Curr Treat Options Neurol</i>. 2013;15(4):454-464.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/23666548/pubmed\" target=\"_blank\" id=\"23666548\">23666548</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Halperin JJ, Shapiro ED, Logigian E, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2007;69(1):91-102. http://www.idsociety.org/uploadedFiles/IDSA/Guidelines-Patient_Care/PDF_Library/Nervous%20System%20Lyme%20Disease.pdf17522387</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hansen JM, Kampmann J, and Laursen H, &ldquo;Renal Excretion of Drugs in the Elderly,&rdquo; <i>Lancet</i>, 1970, 1(657):1170.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy.</i> 2009;29(5):562-577.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19072244\"></a>High KP, Bradley SF, Gravenstein S, et al. Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2009;48(2):149-171.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/19072244/pubmed\" target=\"_blank\" id=\"19072244\">19072244</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hof H, Nichterlein T, Kretschmar M. Management of listeriosis. <i>Clin Microbiol Rev.</i> 1997;10(2):345-357. Review.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/9105758/pubmed\" target=\"_blank\" id=\"9105758\">9105758</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hossain MA, Friciu M, Aubin S, Leclair G. Stability of penicillin G sodium diluted with 0.9% sodium chloride injection or 5% dextrose injection and stored in polyvinyl chloride bag containers and elastomeric pump containers. <i>Am J Health Syst Pharm</i>. 2014;71(8):669-673.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/24688042/pubmed\" target=\"_blank\" id=\"24688042\">24688042</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    King KY. Rat bite fever. Mitty J, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 17, 2017.24688042</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leikola E and Vartia KO, &ldquo;On Penicillin Levels in Young and Geriatric Subjects,&rdquo; <i>J Gerontol</i>, 1957, 12:48-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/13398605/pubmed\" target=\"_blank\" id=\"13398605\">13398605</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mandell LA, Wunderink RG, Anzueto A, at al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. <i>Clin Infect Dis</i>. 2007;44(Suppl 2):S27-S72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/17278083/pubmed\" target=\"_blank\" id=\"17278083\">17278083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matsuda S. Transfer of antibiotics into maternal milk. <i>Biol Res Pregnancy Perinatol.</i> 1984;5(2):57-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/6743732/pubmed\" target=\"_blank\" id=\"6743732\">6743732</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. <i>Emerg Infect Dis</i>. 2014;20(2).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/24457117/pubmed\" target=\"_blank\" id=\"24457117\">24457117</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Medoff G, Kunz LJ, Weinberg AN. Listeriosis in humans: an evaluation. <i>J InfectDis.</i> 1971;123(3):247-250.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/5000073/pubmed\" target=\"_blank\" id=\"5000073\">5000073</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and management of prosthetic joint infection: Clinical Practice Guideline by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2013;56(1):1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12802748\"></a>Panaphut T, Domrongkitchaiporn S, Vibhagool A, Thinkamrop B, Susaengrat W. Ceftriaxone compared with sodium penicillin g for treatment of severe leptospirosis. ftriaxone compared with sodium penicillin g for treatment of severe leptospirosis. <i>Clin Infect Dis</i>. 2003;36(12):1507-1513.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/12802748/pubmed\" target=\"_blank\" id=\"12802748\">12802748</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Penicillin G Potassium Injection [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; November 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pfizerpen [prescribing information]. New York, NY: Roerig; October 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prober CG, Stevenson DK, and Benitz WE, &ldquo;The Use of Antibiotics in Neonates Weighing Less Than 1200 Grams,&rdquo; <i>Pediatr Infect Dis J</i>, 1990, 9(2):111-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/2179837/pubmed\" target=\"_blank\" id=\"2179837\">2179837</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Quagliarello VJ and Scheld WM, &ldquo;Treatment of Bacterial Meningitis,&rdquo; <i>N Engl J Med</i>, 1997, 336(10):708-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/9041103/pubmed\" target=\"_blank\" id=\"9041103\">9041103</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1856121\"></a>Schliamser SE, Cars O, Norrby SR. Neurotoxicity of beta-lactam antibiotics: predisposing factors and pathogenesis. <i>J Antimicrob Chemother</i>. 1991;27(4):405-425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/1856121/pubmed\" target=\"_blank\" id=\"1856121\">1856121</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18291339\"></a>Schneider T, Moos V, Loddenkemper C, Marth T, Fenollar F, Raoult D. Whipple's disease: new aspects of pathogenesis and treatment. <i>Lancet Infect Dis</i>. 2008;8(3):179-190.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/18291339/pubmed\" target=\"_blank\" id=\"18291339\">18291339</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schrag S, Gorwitz R, Fultz-Butts K, et al, &ldquo;Prevention of Perinatal Group B Streptococcal Disease. Revised Guidelines from CDC,&rdquo; <i>MMWR, Recomm Rep</i>, 51(RR11):1-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/12211284/pubmed\" target=\"_blank\" id=\"12211284\">12211284</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15546074\"></a>Suputtamongkol Y, Niwattayakul K, Suttinont C, et al. An open, randomized, controlled trial of penicillin, doxycycline, and cefotaxime for patients with severe leptospirosis.<i>Clin Infect Dis</i>. 2004;39(10):1417-1424.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/15546074/pubmed\" target=\"_blank\" id=\"15546074\">15546074</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. <i>Clin Infect Dis.</i> 2005;41(8):1159-1166.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28203777\"></a>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis [published online February 14, 2017]. <i>Clin Infect Dis</i>. 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/28203777/pubmed\" target=\"_blank\" id=\"28203777\">28203777</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12802749\"></a>Vinetz JM. A mountain out of a molehill: do we treat acute leptospirosis, and if so, with what? <i>Clin Infect Dis</i>. 2003;36(12):1514-1515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/12802749/pubmed\" target=\"_blank\" id=\"12802749\">12802749</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walker MJ, Barnett TC, McArthur JD, et al. Disease manifestations and pathogenic mechanisms of Group A Streptococcus. <i>Clin Microbiol Rev</i>. 2014;27(2):264-301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/24696436/pubmed\" target=\"_blank\" id=\"24696436\">24696436</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Watt G, Padre LP, Tuazon ML. Placebo-controlled trial of intravenous penicillin for severe and late leptospirosis. <i>Lancet</i>.1988;1(8583):433-435.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/2893865/pubmed\" target=\"_blank\" id=\"2893865\">2893865</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wickerts CJ, Asaba H, Gunnarsson B, et al, &ldquo;Combined Carbon Haemoperfusion and Haemodialysis in the Treatment of Penicillin Intoxication,&rdquo; <i>Br Med J</i>, 1980, 280(6226):1254-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization; International Leptospirosis Society. Human leptospirosis: guidance for diagnosis surveillance and control. World Health Organization. http://apps.who.int/iris/bitstream/10665/42667/1/WHO_CDS_CSR_EPH_2002.23.pdf. Published 2003. Accessed August 17, 2016.26042815</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2006;43(9):1089-1134. Erratum in: <i>Clin Infect Dis.</i> 2007;45(7):941.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/17029130/pubmed\" target=\"_blank\" id=\"17029130\">17029130</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wright AJ, &ldquo;The Penicillins,&rdquo; <i>Mayo Clin Proc</i>, 1999, 74(3):290-307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/10090000/pubmed\" target=\"_blank\" id=\"10090000\">10090000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yoshikawa TT, &ldquo;Antimicrobial Therapy for the Elderly Patient,&rdquo; <i>J Am Geriatr Soc</i>, 1990, 38(12):1353-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-intravenous-and-short-acting-intramuscular-drug-information/abstract-text/2254575/pubmed\" target=\"_blank\" id=\"2254575\">2254575</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9749 Version 163.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F207660\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F207661\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F207680\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F207664\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F207675\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F207665\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F207666\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22154815\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F207638\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F207622\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F207642\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F207641\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25860681\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F207689\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F207629\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F207645\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F207626\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299838\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F207631\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5720623\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5707425\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F678881\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F207636\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F207625\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F207644\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323647\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F207648\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9749|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-patient-drug-information\" class=\"drug drug_patient\">Penicillin G (intravenous and short-acting intramuscular): Patient drug information</a></li><li><a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-pediatric-drug-information\" class=\"drug drug_pediatric\">Penicillin G (intravenous and short-acting intramuscular): Pediatric drug information</a></li></ul></div></div>","javascript":null}